NasdaqGS:GILDBiotechs
How Investors Are Reacting To Gilead Sciences (GILD) New HIV Regimen and Liver Disease Milestones
Gilead Sciences and Merck recently reported that their Phase 3 ISLEND-1 and ISLEND-2 trials for a once-weekly oral HIV regimen met primary efficacy and safety goals, while Gilead also announced strong Phase 3 results for Livdelzi in primary biliary cholangitis and secured FDA approval for Hepcludex in hepatitis delta virus.
Together, these developments highlight Gilead’s effort to broaden its portfolio beyond daily HIV therapies, adding long-acting regimens and liver disease treatments that...